Pharmaceutical

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to…

7 months ago

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II…

7 months ago

Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

7 months ago

Akanda Corp Announces Settlement Agreement with Former CEO Tejinder Virk

London, United Kingdom--(Newsfile Corp. - May 13, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), today announced a…

7 months ago

DEA in Disarray: MMJ BioPharma and Other Companies Mount Legal Battle Over Marijuana, Psychedelics, and Violation of Constitutional Rights

DEA FACES FOUR FEDERAL DISTRICT COURT SUITS CLAIMING DISARRAY and CONSTITUTIONAL VIOLATIONS WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024…

7 months ago

Wyoming Department of Corrections and NaphCare Announce Partnership to Provide Comprehensive Healthcare Services Statewide

BIRMINGHAM, Ala. & CHEYENNE, Wyo.--(BUSINESS WIRE)--As a commitment to the safety and well-being of its inmates, the Wyoming Department of…

7 months ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on…

7 months ago

The Association of Cancer Care Centers and Flatiron Health Announce a Strategic Collaboration to Improve Study Data Capture

Partnership to enable cancer care centers to improve access and efficiency of clinical studies and researchNEW YORK--(BUSINESS WIRE)--Flatiron Health, a…

7 months ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP)…

7 months ago

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc…

7 months ago